EAST BRUNSWICK, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. today announced that Paul Hamelin, R.Ph., President of Savient will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at 1:00 p.m. Eastern Time. The conference is being held at The Boston Marriott Copley Place.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
CONTACT: Mary Coleman, Savient Pharmaceuticals, Inc.,
information@savient.com, +1-732-418-9300; or Janelle Saade, Burns
McClellan, jsaade@burnsmc.com, +1-212-213-0006
Web site: http://www.savient.com/
